Titan Pharmaceuticals, Inc.  

(Public, OTCBB:TTNP)   Watch this stock  
Find more results for ttnp
0.480
+0.020 (4.35%)
Nov 26 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.46 - 0.49
52 week 0.44 - 0.90
Open 0.46
Vol / Avg. 278,551.00/180,241.00
Mkt cap 52.80M
P/E     -
Div/yield     -
EPS -0.02
Shares 110.00M
Beta 1.76
Inst. own 4%
Dec 4, 2014
Titan Pharmaceuticals Inc at LD Micro Conference - 11:30AM EST - Add to calendar
Nov 14, 2014
Q3 2014 Titan Pharmaceuticals Inc Earnings Call
Nov 13, 2014
Q3 2014 Titan Pharmaceuticals Inc Earnings Release
Sep 10, 2014
Titan Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 78.59% 92.65%
Operating margin -81.01% -8.50%
EBITD margin - -7.48%
Return on average assets 20.91% 44.91%
Return on average equity 74.46% -
Employees 13 -
CDP Score - -

Address

Suite 505, 400 Oyster Point Blvd
SAN FRANCISCO, CA 94080
United States - Map
+1-415-2444990 (Phone)
+1-650-2444956 (Fax)

Website links

Description

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of the following products: Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders; and Spheramine for the treatment of advanced Parkinson�s disease.Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�s disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders. The Company is also utilizing grants from government agencies to fund development of its product candidates.

Officers and directors

Marc Rubin M.D. Executive Chairman of the Board
Age: 59
Sunil Ramraje Bhonsle President, Director
Age: 63
Joseph A. Akers Director
James R. McNab Jr. Director
Age: 70
Victor J. Bauer Ph.D. Independent Director
Age: 77
Eurelio M. Cavalier Independent Director
Age: 80
Hubert E. Huckel M.D. Independent Director
Age: 82